3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Agastiya Biotech is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | (1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)- 7-(4-hydroxy-3, 5dimethoxyphenyl) hepta- 1, 4, 6-trien-3-one | Des.TrialAppr. |
| adult glioblastoma | (1E,4E,6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one | Des.TrialAppr. |
| glioblastoma | (1E,4E,6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one | Des.TrialAppr. |
| malignant pancreatic neoplasm | (1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3, 5 dimethoxyphenyl) hepta-1, 4, 6-trien-3-one | Des.TrialAppr. |
| mesenchymal glioblastoma | (1E,4E,6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
42
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
42
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio